Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032) Article

Industry Collaboration International Collaboration

cited authors

  • Randall, Leslie M.; O'Malley, David M.; Monk, Bradley J.; Coleman, Robert L.; Gaillard, Stephanie; Adams, Sarah; Duska, Linda R.; Dalton, Heather; Holloway, Robert W.; Huang, Marilyn; Chon, Hye Sook; Cloven, Noelle G.; Elnaggar, Adam C.; O'Cearbhaill, Roisin E.; Waggoner, Steven; Tarkar, Aarti; Striha, Alina; Nelsen, Linda M.; Baines, Amanda; Samnotra, Vivek; Konstantinopoulos, Panagiotis A.

authors

Publication Date

  • November 1, 2023

webpage

published in

category

keywords

  • Available online xxxx
  • Dostarlimab
  • Immunotherapy
  • Niraparib
  • Platinum-resistant ovarian cancer

start page

  • 161

end page

  • 169

volume

  • 178